All > Sle > Michigan

ARV-766 for Hormone-Refractory Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Hormone-Refractory Prostate CancerARV-766 - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will test a new drug, ARV-766, to see if it is safe and effective in treating men with prostate cancer that has spread and is resistant to hormone therapy.

Eligible Conditions
  • Hormone-Refractory Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
RGT-419B
1
ARV-471 in combination with Everolimus
1
Rosuvastatin with/without ARV-471

Study Objectives

7 Primary · 0 Secondary · Reporting Duration: 28 Days

12 Weeks
Part B: To evaluate the clinical anti-tumor activity of ARV-766 in patients with mCRPC
28 Days
Incidence of Dose Limiting Toxicities of ARV-766
Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766
Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766
Part A: Incidence of Dose Limiting Toxicities of ARV-766
Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766
Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
RGT-419B
1
ARV-471 in combination with Everolimus
1
Rosuvastatin with/without ARV-471

Trial Design

3 Treatment Groups

ARV-766 Part A
1 of 3
ARV-766 Part B
1 of 3
ARV-766
1 of 3

Experimental Treatment

150 Total Participants · 3 Treatment Groups

Primary Treatment: ARV-766 · No Placebo Group · Phase 1 & 2

ARV-766 Part A
Drug
Experimental Group · 1 Intervention: ARV-766 Part A · Intervention Types: Drug
ARV-766 Part B
Drug
Experimental Group · 1 Intervention: ARV-766 Part B · Intervention Types: Drug
ARV-766
Drug
Experimental Group · 1 Intervention: ARV-766 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

Arvinas Androgen Receptor, Inc.Lead Sponsor
3 Previous Clinical Trials
296 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have received at least one but no more than three prior second generation anti-androgen agents (e.g.
Participants must have received no more than two prior chemotherapy regimens.
You have adenocarcinoma of the prostate.
You have a performance status of 0 or 1.

Who else is applying?

What state do they live in?
New York100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top